---
schema_version: "secwatch.filing_event.v1"
accession: "0001937653-23-000008"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T10:38:25.218396+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Zymeworks reports FY 2022 net income $124.3M vs loss; $492.2M cash; Jazz deal $375M upfront

## Summary
- Revenue $412.5M (FY22) vs $26.7M (FY21) driven by $375M upfront from Jazz collaboration.
- Net income $124.3M ($1.90 diluted EPS) vs net loss $211.8M in prior year; cash $492.2M through 2026.
- Jazz deal total potential $1.76B; tiered royalties 10-20% on Jazz net sales if approved.
- Zanidatamab: Phase 2 BTC cORR 41.3%, median DOR 12.9 months; GEA 84% OS at 18mo.
- 2023 net cash burn guidance $90-120M incl. $15M capex; zanidatamab zovodotin Phase 2 studies start 2023.

## SEC filing metadata
- accession: 0001937653-23-000008
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765323000008/0001937653-23-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000193765323000008/zyme-20230307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001937653-23-000008
- JSON: https://secwatch.observer/filing/0001937653-23-000008.json
- Plain text: https://secwatch.observer/filing/0001937653-23-000008.txt

## Key facts
- Earnings Releases
  Zymeworks Inc. reported the fourth quarter and year ended December 31, 2022 results: revenue $412.5 million, net income $124.3 million ($1.90 per fully diluted share), EPS $1.90 per fully diluted share.
  - Period: the fourth quarter and year ended December 31, 2022
  - Revenue: $412.5 million
  - Net income: $124.3 million ($1.90 per fully diluted share)
  - EPS: $1.90 per fully diluted share
  - Result: reported results
  source text: Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results • 2022 was a year of transformation and change: ◦ reported $412.5 million in total revenue for the year ended December 31, 2022; ◦ reported net income of $124.3 million ($1.90 per fully diluted share) for 2022 compared to net loss of $211.8 million in 2021;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000193765323000008/0001937653-23-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.